Skip to content

Steven Whittaker

  • Institute of Cancer Research
  • 20h-indexImpact measure calculated using publication and citation counts. Updated daily.
  • 2756CitationsNumber of citations received by Steven's publications. Updated daily.

Other IDs

Research interests

Drug DiscoveryPancreatic cancerColorectal cancerMelanomaFunctional GenomicsDrug Resistance

Co-authors (142)

Publications (5)

  • Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors

    • Whittaker S
    • Cowley G
    • Wagner S
    • et al.
    N/AReaders
    N/ACitations
    Get full text
  • Potent BRAF kinase inhibitors based on 2,4,5-trisubstituted imidazole with naphthyl and benzothiophene 4-substituents

    • Niculescu-Duvaz D
    • Niculescu-Duvaz I
    • Suijkerbuijk B
    • et al.
    N/AReaders
    N/ACitations
    Get full text
  • Corrections to pyridoimidazolones as novel potent inhibitors of v-raf murine sarcoma viral oncogene homologue B1 (BRAF) (Journal of Medicinal Chemistry (2009) 52, (2255-2256) DOI: 10.1021/jm801509w)

    • Niculescu-Duvaz D
    • Gaulon C
    • Dijkstra H
    • et al.
    N/AReaders
    N/ACitations
    Get full text
  • In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202

    • Raynaud F
    • Whittaker S
    • Fischer P
    • et al.
    N/AReaders
    N/ACitations
    Get full text
  • The Cyclin-dependent Kinase Inhibitor CYC202 (R-Roscovitine) Inhibits Retinoblastoma Protein Phosphorylation, Causes Loss of Cyclin D1, and Activates the Mitogen-activated Protein Kinase Pathway

    • Whittaker S
    • Walton M
    • Garrett M
    • et al.
    N/AReaders
    N/ACitations
    Get full text

Professional experience

Institute of Cancer Research